Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jun 10;6(6):CD011330.
doi: 10.1002/14651858.CD011330.pub2.

Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS)

Bushra Naheed  1 , Jan Herman Kuiper  1 , Fidelma O'Mahony  2 , Patrick Ms O'Brien  3
Affiliations
Meta-Analysis

Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS)

Bushra Naheed et al. Cochrane Database Syst Rev. .

Abstract

Background: Premenstrual syndrome (PMS) is a psychological and somatic disorder affecting 20% to 30% of women of reproductive age. PMS results from ovulation: symptoms recur during the luteal phase of the menstrual cycle and remit by the end of menstruation. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS experienced by three to eight per cent of menstruating women. In this review, we use the term PMS to cover all core premenstrual disorders, including PMDD. The symptoms of all types are severe enough to affect daily functioning, interfering with work, school performance or interpersonal relationships. Gonadotropin-releasing hormone (GnRH) analogues are a pharmacological treatment to suppress ovulation. They can be administered as GnRH-agonists or GnRH-antagonists, though currently, GnRH-antagonists are not generally used to treat PMS. Suppressing ovarian function induces a hypo-oestrogenic state that can cause menopausal side effects such as hot flushes and mood changes. Having menopausal side effects instead of PMS symptoms can be distressing and can confuse clinical management. Longer-term GnRH therapy carries the risk of osteoporosis. To counteract these adverse effects, oestrogen or progestogen can be added to the PMS treatment; this is known as 'add-back' therapy or simply 'add-back'. Add-back may reduce menopausal side effects, allowing GnRH therapy to be used for a longer period without reducing efficacy.

Objectives: To evaluate the therapeutic effectiveness and safety (adverse effects) of GnRH analogues (agonists or antagonists), with or without add-back, in the management of PMS.

Search methods: A Cochrane Information Specialist searched the Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO and two trials registers on 29 May 2023. We also checked reference lists and contacted study authors and subject experts to identify additional studies.

Selection criteria: We included randomised controlled trials (RCTs) of GnRH analogues used in the management of PMS in women of reproductive age with PMS diagnosed by at least two prospective menstrual cycles and no current psychiatric disorder. Control conditions could be no treatment, placebo, another type of GnRH, another dosage of GnRH or add-back.

Data collection and analysis: We used the standard methodological procedures recommended by Cochrane. Our primary outcomes were overall severity of PMS symptoms (global symptoms), quality of life and adverse events.

Main results: The review found 11 RCTs that analysed results from 275 women. The evidence is of very low to high certainty. The evidence is limited by serious imprecision due to low sample sizes and a high risk of bias related to blinding and attrition. Quality of life and long-term effects on bones were not reported in the studies. Most studies did not report on all our adverse events of interest; some did not report on any of them. We found no RCTs that evaluated GnRH antagonists. GnRH agonists (without add-back) versus placebo GnRH agonists (without add-back) improve global symptoms compared to placebo (SMD -1.23, 95% CI -1.76 to -0.71; 9 RCTs, 173 women, effective sample size 278; I2 = 72%; high-certainty evidence). GnRH agonists may increase the risk of menopausal side effects compared to placebo (RR 1.93, 95% CI 0.83 to 4.48; 2 RCTs, 23 women, effective sample size 31; low-certainty evidence). If the risk of menopausal side effects with placebo is 21%, the risk with GnRH agonist without add-back would be between 18% and 96%. Seven RCTs reported on withdrawals from the study due to adverse events (though data extraction was not possible for one of these studies). Women using GnRH agonists have a higher risk of withdrawing due to adverse events than women using placebo (RR 4.24, 95% CI 1.10 to 16.36; 6 RCTs, 140 women, effective sample size 252; high-certainty evidence). If the risk of withdrawal from the study is 0.8% with placebo, the withdrawal risk with GnRH agonist without add-back would be between 0.8% and 13%. GnRH agonists (with add-back) versus placebo GnRH agonists with add-back may improve global symptoms compared to placebo (MD -3.89, 95% CI -6.19 to -1.59; 1 RCT, 31 women; low-certainty evidence). We are very uncertain of the effect on withdrawal due to adverse events (RR 2.86, 95% CI 0.12 to 66.44; 1 RCT, 41 women; very low-certainty evidence). Add-back versus placebo add-back during GnRH agonist treatment The evidence of add-back versus placebo during GnRH agonist treatment was too imprecise to decide if there was an effect on global symptoms. The analysis was stratified by type of add-back (tibolone or oestrogen/progesterone). One RCT investigated the effect of tibolone as add-back and found insufficient information to decide if there was an effect on global symptoms (SMD -0.37, 95% CI -0.11 to 0.38; 1 RCT, 28 women; very low-certainty evidence). One RCT investigated the effect of oestrogen plus cyclical progestogen as add-back and found evidence that it may worsen global symptoms compared to placebo (SMD 0.90, 95% CI 0.17 to 1.63; 1 RCT, 32 women; low-certainty evidence). We are very uncertain of the effect of tibolone on withdrawal due to adverse events (RR not estimable; 1 RCT, 28 women; very low-certainty evidence), and of oestrogen plus cyclical progestogen (RR 0.90, 95% CI 0.06 to 13.48; 1 RCT, 40 women; very low-certainty evidence). Add-back dose comparison (low dose versus standard dose) The evidence was too imprecise to determine if a lower add-back dose during GnRH agonist treatment affected global PMS symptoms (MD -11.90, 95% CI -28.51 to 4.71; 1 RCT, 15 women; low-certainty evidence).

Authors' conclusions: This review found that GnRH agonists without add-back improved global symptoms of premenstrual syndrome. However, the induced menopausal side effects and potential complications preclude long-term use. We found insufficient evidence to suggest that side effects can be reduced by 'add-back' without decreasing the global efficacy of GnRH agonists. Further RCTs of GnRH agonists with add-back and long-term follow-up are therefore needed to provide firm conclusions about long-term use. Until data are available to confirm or refute the safety of this combination, GnRH agonists with or without add-back can be administered to provide a short-term break from PMS symptoms. Future studies should attempt to assess the risk of osteoporosis.

PubMed Disclaimer

Conflict of interest statement

BN, JHK FO and PMSO have no interests to declare.

Update of

References

References to studies included in this review

Brown 1994 {published data only}
    1. Brown CS, Ling FW, Anderson RN, Falmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstetrics and Gynecology 1994;84:779–86. - PubMed
Di Carlo 2001 {published data only}
    1. DiCarlo C, Palomba S, Tommaselli GA, Guid M, Di Spiezio Sardo A, Nappi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertility and Sterility 2001;75(2):380–4. - PubMed
    1. Tommaselli GA, Di Carlo C, Bifulco G, Di Spiezio Sardo A, Pellicano M, Nappi C. Serum leptin levels in patients with premenstrual syndrome treated with GnRH analogues alone and in association with tibolone. Clinical Endocrinology 2003;59(6):716-22. - PubMed
Freeman 1997 {published data only}
    1. Freeman EW, Sondheimer SJ, Rickels K. Gonadotrophin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacology Bulletin 1997;33(2):303–9. - PubMed
Hammarback 1988 {published data only}
    1. Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstetricia et Gynecologica Scandinavica 1988;67(2):159-66 PubMed: 3140572. - PubMed
Helvacioglu 1993 {published data only}
    1. Helvacioglu A, Yeoman RR, Hazelton JM, Aksel S. Premenstrual-syndrome and related hormonal changes - long-acting gonadotropin-releasing-hormone agonist treatment. Journal of Reproductive Medicine 1993;38(11):864-70. - PubMed
Hussain 1992 {published data only}
    1. Hussain SY, Massil JH, Matta WH, Shaw RW, O'Brien PMS. Buserelin in premenstrual-syndrome. Gynecological Endocrinology 1992;6(1):57-64. - PubMed
Leather 1999 {published data only}
    1. Leather AT, Studd JWW, Watson NR, Holland EFN. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study. Gynecological Endocrinology 1999;13(1):48-55. - PubMed
Muse 1984 {published data only}
    1. Muse KN, Cetel NS, Futterman LA, Yen SS. The premenstrual syndrome: effects of medical ovariectomy. New England Journal of Medicine 1984;311(212):1345-9. - PubMed
Schmidt 1998 {published data only}
    1. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine 1998;338(4):209-16. - PubMed
Segebladh 2009 {published data only}
    1. Jungheim ES, Kenerson JJ, Foyouzi-Yousefi N, Allsworth JE, Marquard KL. Discussion: 'Add-back regimens in patients using a GnRH agonist for premenstrual dysphoric disorder' by Segebladh et al. American Journal of Obstetrics and Gynecology 2009;201(2):e1-5. - PubMed
    1. Segebladh B, Borgström A, Nyberg S, Bixo M, Sundström-Poromaa I. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. American Journal of Obstetrics & Gynecology 2009;201(139):e1-8. - PubMed
    1. Sundström-Poromaa I. Your 2009 trial on add-back regimens for GnRH agonists [personal communication]. Email (with anonymised data) to: JH Kuiper 30 January 2016.
Sundstrom 1999 {published data only}
    1. Sundstrom I, Nyberg S, Bixo M, Hammarback S, Backstrom T. Treatment of premenstrual syndrome with gonadotrophin releasing hormone agonist in a low dose regimen. Acta Obstetricia et Gynecologica Scandinavica 1999;78(10):891–9. - PubMed

References to studies excluded from this review

Bancroft 1987 {published data only}
    1. Bancroft J, Boyle H, Warner P, Fraser HM. The use of an LHRH agonist, buserelin, in the long‐term management of premenstrual syndromes. Clinical Endocrinology 1987;27:171-82. - PubMed
Mezrow 1994 {published data only}
    1. Mezrow G, Shoupe D, Spicer D. Depot leuprolide acetate with estrogen and progestin addback for long term treatment of premenstrual syndrome. Fertility and Sterility 1994;62:932–7. - PubMed
Mortola 1991 {published data only}
    1. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. Journal of Clinical Endocrinology and Metabolism 1991;72(2):252A-F. - PubMed
Schmidt 2017 {published data only}
    1. Schmidt PJ, Martinez PE, Nieman LK, Koziol DE, Thompson KD, Schenkel L, et al. Exposure to a change in ovarian steroid levels but not continuous stable levels triggers PMDD symptoms following ovarian suppression. American Journal of Psychiatry 2017;174:980-9. - PMC - PubMed
West 1994 {published data only}
    1. West CP, Hillier H. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of premenstrual syndrome. Human Reproduction 1994;9(6):1058–63. - PubMed

Additional references

Abraham 1983
    1. Abraham GE. Nutritional factors in the etiology of the premenstrual tension syndromes. Journal of Reproductive Medicine 1983;28(7):446-64. - PubMed
Backstrom 2011
    1. Bäckström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S, et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 2011;191:46-56. [PMID: PMID: 21600269 [PubMed - indexed for MEDLINE]] - PubMed
Beck 1961
    1. Beck AT, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71. - PubMed
Begg 1996
    1. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9. - PubMed
Bosman 2016
    1. Bosman RC, Jung SE, Miloserdov K, Schoevers RA, aan het Rot M. Daily symptom ratings for studying premenstrual dysphoric disorder: a review. Journal of Affective Disorders. 2016;189:43-53. - PubMed
Bäckström 2003
    1. Bäckström T, Andreen L, Birzniece V, Björn I, Johansson IM, Nordenstam-Haghjo M, et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 2003;17(5):325-42. - PubMed
DSM IV
    1. American Psychiatric Association. DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders. 5th edition (text revision) 2000.
DSM‐5 2013
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-5. Fifth edition. Arlington, VA: American Psychiatric Publishing, 2013.
Endicott 1982
    1. Endicott J, Halbreich U. Retrospective report of premenstrual depressive changes: factors affecting confirmation by daily ratings. Psychopharmacology Bulletin 1982;18(3):109-12.
Endicott 2006
    1. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Archives of Women's Mental Health 2006;9:41–9. - PubMed
Freeman 1996
    1. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Research 1996;65:97-106. - PubMed
Gianetto‐Berruti 2002
    1. Gianetto-Berruti A, Feyles V. Premenstrual syndrome. Minerva Ginecologica 2002;54(2):85-95. [PMID: ] - PubMed
Guy 1976
    1. Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): National Institute of Mental Health, Psychopharmacalogy Research Branch, 1976.
Halbreich 1985
    1. Halbreich U, Endicott J, Lesser J. The clinical diagnosis and classification of premenstrual changes. Canadian Journal of Psychiatry 1985;30:489-97. - PubMed
Haywood 2002
    1. Haywood A, Slade P, King H. Assessing the assessment measures for menstrual cycle symptoms: a guide for researchers and clinicians. Journal of Psychosomatic Research 2002;52(4):223-37. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. - PMC - PubMed
Higgins 2017
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane 2017. Available from https://training.cochrane.org/handbook.
Higgins 2023
    1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook.
ISPMD 2011
    1. O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Archives of Women's Mental Health 2011;14(1):13-21. [PMID: PMID: 21225438 [PubMed - indexed for MEDLINE] - PMC - PubMed
ISPMD 2013
    1. Nevatte T, O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, et al, Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Archives of Women's Mental Health 2013;16(4):279-91. [PMID: PMID: 23624686 [PubMed - indexed for MEDLINE] PMCID: PMC3955202] - PMC - PubMed
Johnson 2004
    1. Johnson S. The epidemiology of premenstrual syndrome. Primary Psychiatry 2004;11(2):27-32.
Kaur 2004
    1. Kaur G, Gonsalves L, Thacker HL. Premenstrual dysphoric disorder: a review for the treating practitioner. Cleveland Clinic Journal of Medicine 2004;71(4):303-5, 312-3, 317-8 passim. [PMID: ] - PubMed
Kiesel 2002
    1. Kiesel LA, Rody A, Greb RR, Szilagyi A. Clinical use of GnRH analogues. Clinical Endocrinology 2002;56(6):677-87. [PMID: ] - PubMed
Knobil 1980
    1. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Progress in Hormone Research 1980;36:53-88. [PMID: ] - PubMed
Liu 2024
    1. Liu X, Li R, Wang S, Zhang J. Global, regional, and national burden of premenstrual syndrome, 1990-2019: an analysis based on the Global Burden of Disease Study 2019. Human Reproduction (Oxford, England) 2024;39(6):1303-15. [DOI: 10.1093/humrep/deae081] - DOI - PubMed
Lopez 2012
    1. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No: CD006586. [DOI: 10.1002/14651858.CD006586.pub4] - DOI - PubMed
Magos 1988
    1. Magos AL. Premenstrual syndrome. Contemporary Reviews in Obstetrics and Gynaecology 1988;1:80-92.
Marjoribanks 2013
    1. Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No: CD001396. [DOI: 10.1002/14651858.CD001396.pub3] - DOI - PMC - PubMed
Millar 2000
    1. Millar RP, Zhu YF, Struthers RS. Progress towards the development of non-peptide orally-active gonadotropin-releasing hormone (GnRH) antagonists: therapeutic implications. British Medical Bulletin 2000;56:761-72. - PubMed
Modi 2024
    1. Modi D, Hussain MS, Ainampudi S, Prajapati BG. Long acting injectables for the treatment of prostate cancer. Journal of Drug Delivery Science and Technology 2024;100:105996. [DOI: 10.1016/j.jddst.2024.105996] - DOI
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535. [PMID: ] - PMC - PubMed
Naheed 2017
    1. Naheed B, Kuiper JH, Uthman OA, O'Mahony F, O'Brien PM. Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome. Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No: CD010503. [DOI: 10.1002/14651858.CD010503.pub2] - DOI - PMC - PubMed
Norman 2003
    1. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical Care 2003;41(3):582-92. - PubMed
O'Brien 2003
    1. O'Brien P, Ismail K, Dimmock P. Premenstrual syndrome. In: Shaw R, Soutter W, Stanton S, editors(s), editors(s). Gynaecology. 3rd edition. London: Churchill Livingston, 2003:401-11.
O'Brien 2007
    1. O'Brien PMS, Rapkin A, Schmidt PJ. PMS and PMDD. In: The Premenstrual Syndromes. 1st edition. CRC Press, 2007.
O'Brien 2011
    1. O'Brien S, Rapkin A, Dennerstein L, Nevatte T. Diagnosis and management of premenstrual disorders. BMJ 2011;342:d2994. [PMID: ] - PubMed
Panay 2005
    1. Panay N. Premenstrual syndrome: making sense of the options. Pulse 2004;65(8):50-4.
Rapkin 2008
    1. Rapkin AJ, Mikacich JA. Premenstrual syndrome and premenstrual dysphoric disorder in adolescents. Current Opinion in Obstetrics and Gynecology 2008;20(5):455-63. - PubMed
RCOG 2017
    1. Green LJ, O’Brien PMS, Panay N, Craig M on behalf of the Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. BJOG 2017;124:e73–e105.
RevMan Web 2024 [Computer program]
    1. Review Manager Web (RevMan Web). Version 7.7.2. The Cochrane Collaboration, 2024. Available at https://revman.cochrane.org/.
Sackett 1996
    1. Sackett DL, Deeks JJ, Altman DG. Down with odds ratios! Evidence Based Medicine 1996;1(6):164-6.
Sanders 1983
    1. Sanders D, Warner P, Bäckström T, Bancroft J. Mood, sexuality, hormones and the menstrual cycle. I. Changes in mood and physical state: description of subjects and method. Psychosomatic Medicine 1983;45(6):487-501. - PubMed
Spielberger 1983
    1. Spielberger CD, Gorsuch RL. State-trait Anxiety Inventory for Adults: Manual and Sample: Manual, Instrument and Scoring Guide. Palo Alto (CA, USA): Mind Garden, 1983.
Steiner 1980
    1. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatrica Scandinavica 1980;62(2):177-90. - PubMed
Tommaselli 2003
    1. Tommaselli GA, Di Carlo C, Bifulco G, Di Spiezio Sardo A, Pellicano M, Nappi C. Serum leptin levels in patients with premenstrual syndrome treated with GnRH analogues alone and in association with tibolone. Clinical Endocrinology 2003;59(6):716-22. - PubMed
Wyatt 2004
    1. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O'Brien PM. The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004;111(6):585-93. [PMID: ] - PubMed

References to other published versions of this review

Naheed 2014
    1. Naheed B, Uthman OA, O'Mahony F, Kuiper JH, O'Brien PMS. Gonadotropin‐releasing hormone (GnRH) analogues for premenstrual syndrome (PMS). Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No: CD011330. [DOI: 10.1002/14651858.CD011330] - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources